Abstract
| Original language | English |
|---|---|
| Journal | Expert Opinion on Drug Metabolism and Toxicology |
| DOIs | |
| Publication status | Published - 2019 |
Cite this
}
Key insights from therapeutic drug monitoring in Crohn’s disease patients. / Seinen, Margien L.; de Boer, Nanne K.; van Bodegraven, Adriaan A.
In: Expert Opinion on Drug Metabolism and Toxicology, 2019.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Key insights from therapeutic drug monitoring in Crohn’s disease patients
AU - Seinen, Margien L.
AU - de Boer, Nanne K.
AU - van Bodegraven, Adriaan A.
PY - 2019
Y1 - 2019
N2 - Introduction: The incidence and prevalence of Crohn’s disease are increasing causing a significant disease burden. Therapeutic drug monitoring (TDM) is advocated as a promising tool for personalized or individual-tailored therapy strategies and has been welcomed as a new means to improve current therapy strategies. Nevertheless, pharmacokinetic-based TDM has limitations, and straightforward target concentrations for most therapies are lacking. Areas covered: In the following concise review of literature, key insights of TDM in thiopurine, methotrexate, anti-TNF, vedolizumab and ustekinumab therapy for Crohn’s disease are being described. Expert opinion: Therapeutic drug monitoring may, up till now, be helpful to adjust thiopurine and infliximab therapy, primarily in a reactive setting, in case of inefficacy and of occurrence of adverse event. With this restricted application, the goal of individualized therapy based on TDM has not yet been achieved.
AB - Introduction: The incidence and prevalence of Crohn’s disease are increasing causing a significant disease burden. Therapeutic drug monitoring (TDM) is advocated as a promising tool for personalized or individual-tailored therapy strategies and has been welcomed as a new means to improve current therapy strategies. Nevertheless, pharmacokinetic-based TDM has limitations, and straightforward target concentrations for most therapies are lacking. Areas covered: In the following concise review of literature, key insights of TDM in thiopurine, methotrexate, anti-TNF, vedolizumab and ustekinumab therapy for Crohn’s disease are being described. Expert opinion: Therapeutic drug monitoring may, up till now, be helpful to adjust thiopurine and infliximab therapy, primarily in a reactive setting, in case of inefficacy and of occurrence of adverse event. With this restricted application, the goal of individualized therapy based on TDM has not yet been achieved.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85064677132&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30892105
U2 - 10.1080/17425255.2019.1597054
DO - 10.1080/17425255.2019.1597054
M3 - Article
JO - Expert Opinion on Drug Metabolism and Toxicology
JF - Expert Opinion on Drug Metabolism and Toxicology
SN - 1742-5255
ER -